Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYGJQO)

Drug Name
Ponatinib Drug Info
Synonyms Iclusig (TN)
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [2]
Thyroid tumor Approved [2]
Cross-matching ID
PubChem CID
24826799
ChEBI ID
CHEBI:78543
CAS Number
CAS 943319-70-8
TTD Drug ID
DMYGJQO
VARIDT Drug ID
DR00204
INTEDE Drug ID
DR1315
ACDINA Drug ID
D00541

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [8]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [9]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [10]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [3]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [11]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [12]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [13]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [14]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [15]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Ret (RET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [17]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [3]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [8]
Selpercatinib DMZR15V Non-small-cell lung cancer 2C25.Y Approved [18]
Pralsetinib DMWU0I2 Non-small-cell lung cancer 2C25.Y Approved [19]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [20]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [21]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [22]
GSK3179106 DM2KCIP Inflammatory bowel disease DD72 Phase 1 [23]
BOS172738 DM9L0D8 Solid tumour/cancer 2A00-2F9Z Phase 1 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase ABL1 (ABL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [8]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [25]
Adenosine triphosphate DM79F6G Malnutrition 5B50-5B71 Approved [26]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [27]
Flumatinib DM0G5O6 Chronic myelogenous leukaemia 2A20.0 Phase 2 [28]
DCC-2036 DMJKFNU Chronic myeloid leukaemia 2A20 Phase 1/2 [29]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [30]
KW-2449 DMFO7RP Acute myeloid leukaemia 2A60 Phase 1 [31]
IkT-148009 DMMJ9HY Parkinson disease 8A00.0 Phase 1 [32]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [34]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [35]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [8]
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [36]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [12]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [34]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [21]
Lestaurtinib DMQ2AIJ Acute myeloid leukaemia 2A60 Approved (orphan drug) [37]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [14]
BMS-690514 DMX302C Chronic pain MG30 Phase 2 [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [39]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [40]
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Folic Acid DMEMBJC Colorectal carcinoma Approved [42]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [41]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [41]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [43]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [41]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [44]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Folic Acid DMEMBJC Colorectal carcinoma Approved [48]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [49]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [50]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [51]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [52]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [53]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [55]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [56]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [57]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [58]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [59]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [60]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [61]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [62]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [56]
Verapamil DMA7PEW Angina pectoris BA40 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [64]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [65]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [66]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [59]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [63]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [67]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [68]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [69]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [70]
Propranolol DM79NTF Angina pectoris BA40 Approved [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [72]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [73]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [74]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [75]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [76]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [77]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [78]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [79]
Verapamil DMA7PEW Angina pectoris BA40 Approved [80]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [75]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [3]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Modulator [3]
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Modulator [3]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [4]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
2 Ponatinib FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
5 Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
6 Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
7 Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
10 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
11 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
14 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
15 National Cancer Institute Drug Dictionary (drug id 452042).
16 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
17 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 National Cancer Institute Drug Dictionary (drug name Zeteletinib).
25 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
26 Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
27 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
28 Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
29 Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
30 Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
31 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
32 The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.
33 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
35 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
36 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
37 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
38 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
39 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
47 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
48 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
49 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
50 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
51 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
52 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
53 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
54 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
55 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
56 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
57 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
58 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
59 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
60 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
61 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
62 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
63 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
64 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
65 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
66 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
67 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
68 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
69 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
70 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
71 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
72 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
73 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
74 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
75 Drug Interactions Flockhart Table
76 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
77 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
78 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
79 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
80 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.